Jupiter Life Lin
Jupiter Life Lin Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #30 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 4 strong
The short version
Dombivli Hospital's patient footfall is gradually increasing month-on-month, ramping up as expected. Jupiter Life Line Hospitals expects steady growth primarily driven by ramp-up in newer hospitals like Dombivli, which is gradually increasing patient footfall and aiming to breakeven in its second year.
From Jupiter Life Lin's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Dombivli Hospital's patient footfall is gradually increasing month-on-month, ramping up as expected.
- Revenue growth for mature hospitals (Thane and Pune) expected mostly in line with inflationary price hikes; Pune may see slower growth as it approaches higher occupancy (~75%).
- Indore and Dombivli hospitals have room for faster revenue growth due to occupancy expansions.
- ARPOB (Average Revenue per Occupied Bed) growth driven by case mix improvement and pricing renegotiations; expected to grow higher than inflation initially for new units, later aligning with inflation.
- Overall growth expected around 13-16% for existing units, with Dombivli continuing its ramp-up.
2 more points from Jupiter Life Lin's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jupiter Life Lin said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for current and upcoming hospital projects is ongoing and detailed in the financial presentation; internal accruals and cash on hand are expected to cover the next few years of capex.
- Towards the end of the current capex cycle, some additional debt may be explored but will remain within a board-imposed ceiling of 3x EBITDA.
- Jupiter recently acquired a company to set up an IV fluids manufacturing unit as a backward integration for its pharmacy subsidiary, aiming for cost management and margin improvement.
- The IV fluids manufacturing plant involves a capex of around INR 35-40 crores including infrastructure.
2 more points from Jupiter Life Lin's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jupiter Life Lin said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Jupiter Life Line Hospitals has 3 upcoming projects currently on track as mentioned by the management.
- The company plans to complete these 3 projects within the next 5 years.
- Focus remains on expanding hospital presence primarily in Western India.
2 more points from Jupiter Life Lin's call on order book
Create a free account to keep reading this call
Jupiter Life Lin — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹456 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jupiter Life Lin's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital Ltd (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jupiter Life Lin and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jupiter Life Lin Q1 FY27 results?
Dombivli Hospital's patient footfall is gradually increasing month-on-month, ramping up as expected. Jupiter Life Line Hospitals expects steady growth primarily driven by ramp-up in newer hospitals like Dombivli, which is gradually increasing patient footfall and aiming to breakeven in its second year.
What is Jupiter Life Lin share price analysis?
Jupiter Life Lin currently shows a below-average growth signal. The stock trades at a P/E of 53.1 with a market cap of ₹10,155 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jupiter Life Lin planning capital expenditure?
Capex for current and upcoming hospital projects is ongoing and detailed in the financial presentation; internal accruals and cash on hand are expected to cover the next few years of capex.
Keep Jupiter Life Lin on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.